Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer

Cell Cycle

Volumn 10, Issue 18, 2011, Pages 3119-3128

  Luchenko, Victoria L ^a   Salcido, Crystal D ^a,b   Zhang, Yongwei ^a   Agama, Keli ^a   Komlodi Pasztor, Edina ^a   Murphy, Robert F ^a   Giaccone, Giuseppe ^a   Pommier, Yves ^a   Bates, Susan E ^a   Varticovski, Lyuba ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Combination index; Drug interaction; dsDNA break; PARP degradation; Synergy; H2AX phosphorylation

Indexed keywords

BELINOSTAT; CISPLATIN; DOUBLE STRANDED DNA; ETOPOSIDE; HISTONE DEACETYLASE INHIBITOR; HISTONE H2AX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ROMIDEPSIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE; CELL CYCLE ARREST; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DOSAGE SCHEDULE COMPARISON; DOUBLE STRANDED DNA BREAK; DRUG ANTAGONISM; DRUG DNA BINDING; DRUG EFFICACY; DRUG POTENTIATION; HISTONE ACETYLATION; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; MATHEMATICAL MODEL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION;

EID: 80052944398     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.18.17190     Document Type: Article

References (48)

1. Felsenfeld G, Groudine M. Controlling the double helix. Nature 2003; 421:448-53; PMID:12540921.
2. Becker PB, Hörz W. ATP-dependent nucleosome remodeling. Annu Rev Biochem 2002; 71:247-73; PMID:12045097.
3. Holbert MA, Marmorstein R. Structure and activity of enzymes that remove histone modifications. Curr Opin Struct Biol 2005; 15:673-80; PMID:16263263.
4. Turner BM. Reading signals on the nucleosome with a new nomenclature for modified histones. Nat Struct Mol Biol 2005; 12:110-2; PMID:15702071.
5. Minucci S, Pelicci P. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6:38-51; PMID:16397526.
6. Xu WS, Parmigiani R, Marks P. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26:5541-52; PMID:17694093.
7. Zhou Q, Melkoumian Z, Lucktong A, Moniwa M, Davie J, Strobl J. Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1. J Biol Chem 2000; 275:35256-63; PMID:10938272.
8. Schrump DS. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin Cancer Res 2009; 15:3947-57; PMID:19509170.
9. Sikandar S, Dizon D, Shen X, Li Z, Besterman J, Lipkin SM. The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and noncanonical Wnt signaling. Oncotarget 2010; 1:596-605; PMID:21317455.
10. Keshelava N, Davicioni E, Wan Z, Ji L, Sposto R, Triche T, et al. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. J Natl Cancer Inst 2007; 99:1107-19; PMID:17623797.
11. Kim MS, Blake M, Baek J, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003; 63:7291-300; PMID:14612526.
12. Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, et al. Histone deacetylase inhibitor LAQ824 downregulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine and epothilone B. Mol Cancer Ther 2003; 2:971-84; PMID:14578462.
13. Zhang Y, Jung M, Dritschilo A. Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors. Radiat Res 2004; 161:667-74; PMID:15161353.
14. Camphausen K, Tofilon P. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J Clin Oncol 2007; 25:4051-6; PMID:17827453.
15. Glaser KB. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 2007; 74:659-71; PMID:17498667.
16. Puglisi M, Dolly S, Faria A, Myerson J, Popat S, O'Brien M. Treatment options for small cell lung cancer - do we have more choice? Br J Cancer 2010; 102:629-38; PMID:20104223.
17. Steele NL, Plumb J, Vidal L, Tjørnelund J, Knoblauch P, Rasmussen A, et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008; 14:804-10; PMID:18245542.
18. Bates SE, Zhan Z, Steadman K, Obrzut T, Luchenko V, Frye R, et al. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol 2010; 148:256-67; PMID:19874311.
19. Lane AA, Chabner B. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27:5459-68; PMID:19826124.
20. Romanov VS, Abramova MV, Svetlikova SB, Bykova TV, Zubova SG, Aksenov ND, et al. p21(Waf1) is required for cellular senescence but not for cell cycle arrest induced by the HDAC inhibitor sodium butyrate. Cell Cycle 2010; 9:3945-55; PMID:20935470.
21. Rosato RR, Almenara J, Maggio S, Coe S, Atadja P, Dent P, et al. Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions. Mol Cancer Ther 2008; 7:3285-97; PMID:18852132.
22. Kurz EU, Wilson S, Leader K, Sampey B, Allan W, Yalowich J, et al. The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol Cancer Ther 2001; 1:121-31; PMID:12467229.
23. Tanaka T, Halicka HD, Traganos F, Seiter K, Darzynkiewicz Z. Induction of ATM activation, histone H2AX phosphorylation and apoptosis by etoposide: relation to cell cycle phase. Cell Cycle 2007; 6:371-6; PMID:17297310.
24. Schonn I, Hennesen J, Dartsch D. Cellular responses to etoposide: cell death despite cell cycle arrest and repair of DNA damage. Apoptosis 2010; 15:162-72; PMID:20041303.
25. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson N, Poirier G. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 1993; 53:3976-85; PMID:8358726.
26. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009; 9:338-50; PMID:19377506.
27. Kohn KW. DNA filter elution: a window on DNA damage in mammalian cells. Bioessays 1996; 18:505-13; PMID:8787538.
28. Bonner WM, Redon C, Dickey J, Nakamura A, Sedelnikova O, Solier S, et al. GammaH2AX and cancer. Nat Rev Cancer 2008; 8:957-67; PMID:19005492.
29. Sokolov MV, Dickey JS, Bonner WM, Sedelnikova OA. gammaH2AX in bystander cells: not just a radiation-triggered event, a cellular response to stress mediated by intercellular communication. Cell Cycle 2007; 6:2210-2; PMID:17881892.
30. Nakamura AJ, Rao VA, Pommier Y, Bonner WM. The complexity of phosphorylated H2AX foci formation and DNA repair assembly at DNA double-strand breaks. Cell Cycle 2010; 9:389-97; PMID:20046100.
31. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70:440-6; PMID:20068163.
32. Sato T, Suzuki M, Sato Y, Echigo S, Rikiishi H. Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells. Int J Oncol 2006; 28:1233-41; PMID:16596240.
33. Hajji N, Wallenborg K, Vlachos P, Nyman U, Hermanson O, Joseph B. Combinatorial action of the HDAC inhibitor trichostatin A and etoposide induces caspase-mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells. Oncogene 2008; 27:3134-44; PMID:18071312.
34. Piekarz RL, Bates S. Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res 2009; 15:3918-26; PMID:19509169.
35. Miller KM, Tjeertes JV, Coates J, Legube G, Polo SE, Britton S, et al. Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining. Nat Struct Mol Biol 2010; 17:1144-51; PMID:20802485.
36. Bruzzese F, Rocco M, Castelli S, Di Gennaro E, Desideri A, Budillon A. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol Cancer Ther 2009; 8:3075-87; PMID:19887547.
37. Yu C, Friday B, Lai J, McCollum A, Atadja P, Roberts L, et al. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation. Clin Cancer Res 2007; 13:1140-8; PMID:17317822.
38. Munshi A, Tanaka T, Hobbs M, Tucker S, Richon V, Meyn R. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gammaH2AX foci. Mol Cancer Ther 2006; 5:1967-74; PMID:16928817.
39. Robles AI, Wright M, Gandhi B, Feis S, Hanigan C, Wiestner A, et al. Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines. Clin Cancer Res 2006; 12:6547-56; PMID:17085670.
40. Koll TT, Feis S, Wright M, Teniola M, Richardson M, Robles A, et al. HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair. Mol Cancer Ther 2008; 7:1985-92; PMID:18645008.
41. Bevins RL, Zimmer S. It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells. Cancer Res 2005; 65:6957-66; PMID:16061681.
42. de Ruijter AJ, Leen R, Hoebink J, Caron H, van Kuilenburg A. Antagonistic effects of sequential administration of BL1521, a histone deacetylase inhibitor and gemcitabine to neuroblastoma cells. Cancer Lett 2006; 233:240-6; PMID:15907366.
43. Conti C, Leo E, Eichler G, Sordet O, Martin M, Fan A, et al. Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins and induces DNA damage. Cancer Res 2010; 70:4470-80; PMID:20460513.
44. Harr MW, Willey J. The interactive transcript abundance index [c-myc*p73alpha]/[p21*Bcl-2] correlates with baseline level of apoptosis and response to CPT- 11 in human bronchogenic carcinoma cell lines. Int J Oncol 2007; 30:1553-60; PMID:17487378.
45. Kaye FJ. Molecular biology of lung cancer. Lung Cancer 2001; 34:35-41; PMID:11720739.
46. Rabik CA, Fishel M, Holleran J, Kasza K, Kelley M, Egorin M, et al. Enhancement of cisplatin [cis-diammine dichloroplatinum (II)] cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress. J Pharmacol Exp Ther 2008; 327:442-52; PMID:18664592.
47. McGahan MC, Tyczkowska K. The determination of platinum in biological materials by electrothermal atomic absorption spectroscopy. Spectrochimia Acta 1987; 42:665. PMID:509738.
48. Zhang YW, Jones T, Martin S, Caplen N, Pommier Y. Implication of checkpoint kinase-dependent upregulation of ribonucleotide reductase R2 in DNA damage response. J Biol Chem 2009; 284:18085-95; PMID:19416980.